{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:27:22Z","timestamp":1784716042448,"version":"3.55.0"},"reference-count":177,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Over the past few decades, the field of cancer therapy has seen a significant change in the way in which formulations are designed and developed, resulting in more efficient products that allow us to ultimately achieve improved drug bioavailability, efficacy, and safety. However, although many formulations have entered the market, many others have fallen by the wayside leaving the scientific community with several lessons to learn. The successes (and failures) achieved with formulations that have been approved in Europe and\/or by the FDA for the three major types of cancer therapy (peptide-based therapy, chemotherapy, and radiotherapy) are reviewed herein, covering the period from the approval of the first prolonged-release system for hormonal therapy to the appearance of the first biodegradable microspheres intended for chemoembolization in 2020. In addition, those products that have entered phase III clinical trials that have been active over the last five years are summarized in order to outline future research trends and possibilities that lie ahead to develop clinically translatable formulations for cancer treatment.<\/jats:p>","DOI":"10.3390\/pharmaceutics12111028","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T23:06:12Z","timestamp":1604012772000},"page":"1028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom"],"prefix":"10.3390","volume":"12","author":[{"given":"Alexandre","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00edn-Sabroso","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-6177","authenticated-orcid":false,"given":"Ana Isabel","family":"Torres-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-4568","authenticated-orcid":false,"given":"Juan","family":"Aparicio-Blanco","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A History of Cancer Chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"761820","DOI":"10.1155\/2015\/761820","article-title":"Peptide-Based Treatment: A Promising Cancer Therapy","volume":"2015","author":"Xiao","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PPO.0000000000000428","article-title":"Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer","volume":"26","author":"Barata","year":"2020","journal-title":"Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/967347","article-title":"Cancer Treatment Using Peptides: Current Therapies and Future Prospects","volume":"2012","author":"Thundimadathil","year":"2012","journal-title":"J. Amino Acids"},{"key":"ref_8","unstructured":"Zafar, S., Beg, S., Panda, S.K., Rahman, M., Alharbi, K.S., Jain, G.K., and Ahmad, F.J. (2019). Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems. Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.nano.2014.04.012","article-title":"Drug delivery: Beyond active tumour targeting","volume":"10","author":"Sagnella","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_12","first-page":"1","article-title":"Radiotherapy toxicity","volume":"5","author":"Niedermann","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2005.07.030","article-title":"Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory","volume":"314","author":"Faisant","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","article-title":"In situ forming implants\u2014An attractive formulation principle for parenteral depot formulations","volume":"161","author":"Kempe","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hrkach, J., and Langer, R. (2020). From micro to nano: Evolution and impact of drug delivery in treating disease. Drug Deliv. Transl. Res., 10.","DOI":"10.1007\/s13346-020-00769-6"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.msec.2019.01.066","article-title":"Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer","volume":"98","author":"Kalyane","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","article-title":"Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status","volume":"65","author":"Vehmeijer","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119283","DOI":"10.1016\/j.ijpharm.2020.119283","article-title":"Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy","volume":"581","author":"Lorenzoni","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1600766","DOI":"10.1002\/adhm.201600766","article-title":"Biomaterial-Based Implantable Devices for Cancer Therapy","volume":"6","author":"Chew","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: A comprehensive review of the literature","volume":"2","author":"Bazak","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.7150\/thno.37204","article-title":"Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery","volume":"9","author":"Dhaliwal","year":"2019","journal-title":"Theranostics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jasim, A., Abdelghany, S., and Greish, K. (2017). Current Update on the Role of Enhanced Permeability and Retention Effect in Cancer Nanomedicine. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes, Elsevier Inc.","DOI":"10.1016\/B978-0-12-809717-5.00002-6"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wu, L., Tao, A., Bera, H., Tang, X., Cun, D., and Yang, M. (2020). Formulation and in vitro characterization of long-acting PLGA injectable microspheres encapsulating a peptide analog of LHRH. J. Mater. Sci. Technol.","DOI":"10.1016\/j.jmst.2020.04.020"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jconrel.2020.01.023","article-title":"Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic acid) microspheres by spray-drying","volume":"321","author":"Shi","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.addr.2016.07.002","article-title":"Injectable formulations of poly(lactic acid) and its copolymers in clinical use","volume":"107","author":"Jain","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2010.05.011","article-title":"Issues in long-term protein delivery using biodegradable microparticles","volume":"146","author":"Ye","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drudis.2014.09.018","article-title":"Hybrid poly(lactic-co-glycolic acid) nanoparticles: Design and delivery prospectives","volume":"20","author":"Pandita","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13233-012-0123-1","article-title":"Triptorelin acetate-loaded poly(lactide-co-glycolide) (PLGA) microspheres for controlled drug delivery","volume":"20","author":"Park","year":"2012","journal-title":"Macromol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.jddst.2019.101390","article-title":"Novel triptorelin acetate-loaded microspheres prepared by a liquid\/oil\/oil method with high encapsulation efficiency and low initial burst release","volume":"54","author":"Chen","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jconrel.2019.03.002","article-title":"(Jeff) Complex sameness: Separation of mixed poly(lactide-co-glycolide)s based on the lactide:glycolide ratio","volume":"300","author":"Skidmore","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000474238","article-title":"Randomized Open Labelled Comparative Study of the Efficacy, Safety and Tolerability of Leuprorelin Acetate 1M and 3M Depot in Patients with Advanced Prostatic Cancer","volume":"30","author":"Wechsel","year":"1996","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.05.003","article-title":"Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation","volume":"304","author":"Park","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: A Review in Acute Lymphoblastic Leukaemia","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Meneguetti, G.P., Santos, J.H.P.M., Obreque, K.M.T., Barbosa, C.M.V., Monteiro, G., Farsky, S.H.P., Marim de Oliveira, A., Angeli, C.B., Palmisano, G., and Ventura, S.P.M. (2019). Novel site-specific PEGylated L-asparaginase. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211951"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"Sulheim","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cpt.71","article-title":"Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier","volume":"97","author":"Parrish","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2018.12.048","article-title":"Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer","volume":"295","author":"Serra","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijpharm.2018.10.011","article-title":"The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system","volume":"552","author":"Xiao","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nnano.2017.61","article-title":"Evolution of the nanoparticle corona","volume":"12","author":"Hadjidemetriou","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tibtech.2016.08.011","article-title":"Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona","volume":"35","author":"Caracciolo","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2019.11.016","article-title":"A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market","volume":"317","author":"Mignani","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of Pegylated Liposomal Doxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00280-017-3412-8","article-title":"Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin","volume":"80","author":"Blank","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejps.2011.09.006","article-title":"Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy","volume":"45","author":"Gabizon","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s002800000206","article-title":"Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia","volume":"47","author":"Bellott","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/IJN.S26766","article-title":"Clinical development of liposome based drugs: Formulation, characterization, and therapeutic efficacy","volume":"7","author":"Yeh","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","article-title":"Clinical cancer nanomedicine","volume":"25","author":"Wolfram","year":"2019","journal-title":"Nano Today"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0163-7827(02)00004-8","article-title":"A lipid based depot (DepoFoam\u00ae technology) for sustained release drug delivery","volume":"41","author":"Mantripragada","year":"2002","journal-title":"Prog. Lipid Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.ejmp.2016.10.023","article-title":"Calculation of tumour and normal tissue biological effective dose in 90 Y liver radioembolization with different dosimetric methods","volume":"32","author":"Gallio","year":"2016","journal-title":"Phys. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2967\/jnumed.119.232751","article-title":"First Evidence for a Dose-Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study","volume":"61","author":"Bastiaannet","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3348\/kjr.2016.17.4.472","article-title":"Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review","volume":"17","author":"Lee","year":"2016","journal-title":"Korean J. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.14309\/01.ajg.0000593448.20328.07","article-title":"Prolonged Survival With Radioembolization Using Theraspheres in Unresectable HCC","volume":"114","author":"Mantry","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semradonc.2011.05.004","article-title":"Radioembolization for Primary and Metastatic Liver Cancer","volume":"21","author":"Memon","year":"2011","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Desai, N. (2016). Nanoparticle Albumin-Bound Paclitaxel (Abraxane\u00ae). Albumin in Medicine, Springer.","DOI":"10.1007\/978-981-10-2116-9_6"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: What has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rpor.2017.02.007","article-title":"Other non-surgical treatments for liver cancer","volume":"22","author":"Otal","year":"2017","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chew, S.A., Moscato, S., George, S., Azimi, B., and Danti, S. (2019). Liver Cancer: Current and Future Trends Using Biomaterials. Cancers, 11.","DOI":"10.3390\/cancers11122026"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3348\/kjr.2015.16.1.125","article-title":"Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma","volume":"16","author":"Liu","year":"2015","journal-title":"Korean J. Radiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(01)00358-3","article-title":"An in vivo\/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer","volume":"75","author":"Wright","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eursup.2010.08.004","article-title":"Introducing Vantas: The First Once-Yearly Luteinising Hormone-Releasing Hormone Agonist","volume":"9","author":"Shore","year":"2010","journal-title":"Eur. Urol. Suppl."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CEOR.S44855","article-title":"Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: Evidence review and economic evaluation","volume":"5","author":"Wex","year":"2013","journal-title":"Clin. Outcomes Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1756287217738150","article-title":"Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects","volume":"10","author":"Saltzstein","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00520-018-4054-z","article-title":"Symptom management: The utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer","volume":"26","author":"Bun","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2017.1380655","article-title":"Advances in nano-delivery systems for doxorubicin: An updated insight","volume":"26","author":"Kanwal","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.01.002","article-title":"Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations","volume":"519","author":"Luo","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","article-title":"Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Resu","volume":"17","author":"Batist","year":"2006","journal-title":"Anticancer. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: A next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/nnm-2018-0313","article-title":"Nanopaclitaxel therapy: An evidence based review on the battle for next-generation formulation challenges","volume":"14","author":"Barkat","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3348\/kjr.2018.0088","article-title":"Il Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma","volume":"20","author":"Nouri","year":"2019","journal-title":"Korean J. Radiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fchem.2019.00408","article-title":"Recent Advances on Polymeric Beads or Hydrogels as Embolization Agents for Improved Transcatheter Arterial Chemoembolization (TACE)","volume":"7","author":"Chen","year":"2019","journal-title":"Front. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/kjhep.2011.17.1.51","article-title":"Optimal technique and response of doxorubicin beads in hepatocellular cancer: Bead size and dose","volume":"17","author":"Martin","year":"2011","journal-title":"Korean J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/hep.13.18","article-title":"Chemoembolization with DC BeadTM for the treatment of hepatocellular carcinoma: An update","volume":"1","author":"Malagari","year":"2014","journal-title":"Hepatic Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jvir.2009.10.038","article-title":"Transarterial Chemoembolization with Epirubicin-eluting Beads versus Transarterial Embolization before Liver Transplantation for Hepatocellular Carcinoma","volume":"21","author":"Nicolini","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MEG.0b013e328346d505","article-title":"Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"23","author":"Song","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cgh.2007.04.021","article-title":"A Phase I\/II Trial of Chemoembolization for Hepatocellular Carcinoma Using a Novel Intra-Arterial Drug-Eluting Bead","volume":"5","author":"Poon","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00270-013-0777-x","article-title":"Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30\u201360 \u03bcm. Safety and Efficacy Study","volume":"37","author":"Malagari","year":"2014","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1435302","article-title":"Transarterial Radioembolization (TARE) Agents beyond 90 Y-Microspheres","volume":"2018","author":"Bouvry","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1078-0432.CCR-19-2975","article-title":"Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia","volume":"26","author":"Lew","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1200\/JCO.2019.37.15_suppl.10006","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia\/lymphoma: Results of DFCI 11-001","volume":"37","author":"Vrooman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","article-title":"Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia","volume":"21","author":"Douer","year":"2016","journal-title":"Oncologist"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.2147\/IJN.S54657","article-title":"Vincristine sulfate liposomal injection for acute lymphoblastic leukemia","volume":"8","author":"Moore","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14737140.2016.1192471","article-title":"The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy","volume":"16","author":"Passero","year":"2016","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/OTT.S141212","article-title":"Reformulating acute myeloid leukemia: Liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML","volume":"11","author":"Chen","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","volume":"326","author":"Germain","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tzogani, K., Penttil\u00e4, K., Lapvetel\u00e4inen, T., Hemmings, R., Koenig, J., Freire, J., M\u00e1rcia, S., Cole, S., Coppola, P., and Flores, B. (2020). EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Oncologist.","DOI":"10.1634\/theoncologist.2019-0785"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s12325-019-01058-6","article-title":"Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients","volume":"36","author":"Lilienberg","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jvir.2014.08.021","article-title":"Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics","volume":"26","author":"Guiu","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2217\/fon-2018-0237","article-title":"Liver chemoembolization of hepatocellular carcinoma using TANDEM\u00ae microspheres","volume":"14","author":"Delicque","year":"2018","journal-title":"Futur. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00270-017-1839-2","article-title":"Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study","volume":"41","author":"Richter","year":"2018","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2214\/AJR.16.17477","article-title":"Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma","volume":"209","author":"Aliberti","year":"2017","journal-title":"Am. J. Roentgenol."},{"key":"ref_106","first-page":"3515","article-title":"Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy","volume":"36","author":"Aliberti","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbrc.2015.09.027","article-title":"Metals as radio-enhancers in oncology: The industry perspective","volume":"468","author":"Pottier","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.semnuclmed.2019.01.008","article-title":"Holmium-166 Microsphere Radioembolization of Hepatic Malignancies","volume":"49","author":"Reinders","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2\u20133, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"119098","DOI":"10.1016\/j.ijpharm.2020.119098","article-title":"Nanopharmaceuticals: A focus on their clinical translatability","volume":"578","author":"Bisso","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"TPS551","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS551","article-title":"A phase I\/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers","volume":"36","author":"Chajon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10563","DOI":"10.1200\/jco.2014.32.15_suppl.10563","article-title":"Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS)","volume":"32","author":"Bonvalot","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","article-title":"First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas","volume":"23","author":"Bonvalot","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-018-03005-x","article-title":"Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients","volume":"141","author":"Grauer","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1080\/02656736.2018.1430867","article-title":"Magnetic hyperthermia therapy for the treatment of glioblastoma: A review of the therapy\u2019s history, efficacy and application in humans","volume":"34","author":"Mahmoudi","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"011502","DOI":"10.1063\/1.5079943","article-title":"Nanostructured carriers as innovative tools for cancer diagnosis and therapy","volume":"3","author":"Martinelli","year":"2019","journal-title":"APL Bioeng."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2217\/nnm-2017-0336","article-title":"Magnetic iron oxide nanoparticles as drug carriers: Clinical relevance","volume":"13","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","article-title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma","volume":"29","author":"Qin","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2017-0338","article-title":"HALO-109\u2013301: A Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer","volume":"14","author":"Doherty","year":"2018","journal-title":"Futur. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/213848","article-title":"Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations","volume":"2011","author":"Zisman","year":"2011","journal-title":"Chemother. Res. Pract."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Osada, A. (2019). NC-6004, a novel cisplatin nanoparticle, in combination with pembrolizumab for head and neck cancer. Integr. Clin. Med., 3.","DOI":"10.15761\/ICM.1000147"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jconrel.2019.06.012","article-title":"Heat-activated drug delivery increases tumor accumulation of synergistic chemotherapies","volume":"308","author":"Dunne","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jvir.2011.10.018","article-title":"Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies","volume":"23","author":"Wood","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(19)30040-8","article-title":"Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): A phase 3 randomised controlled trial","volume":"4","author":"Merle","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ignatiadis, M., Zardavas, D., Lemort, M., Wilke, C., Vanderbeeken, M.-C., D\u2019Hondt, V., De Azambuja, E., Gombos, A., Lebrun, F., and Dal Lago, L. (2016). Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154009"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bjc.6603311","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel","volume":"95","author":"Negishi","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2217\/fon-2019-0180","article-title":"ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician\u2019s choice in patients with metastatic breast cancer and brain metastases","volume":"15","author":"Tripathy","year":"2019","journal-title":"Futur. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fbioe.2020.00381","article-title":"PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications","volume":"8","author":"Shen","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.apsb.2019.08.003","article-title":"Recent progress in drug delivery","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Pillai, G. (2014). Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. SOJ Pharm. Pharm. Sci.","DOI":"10.15226\/2374-6866\/1\/2\/00109"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Baeza, A. (2020). Tumor Targeted Nanocarriers for Immunotherapy. Molecules, 25.","DOI":"10.3390\/molecules25071508"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","article-title":"Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine","volume":"30","author":"Pearce","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"045102","DOI":"10.1088\/0957-4484\/19\/04\/045102","article-title":"Folate-conjugated polymer micelles for active targeting to cancer cells: Preparation, in vitro evaluation of targeting ability and cytotoxicity","volume":"19","author":"You","year":"2008","journal-title":"Nanotechnology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00894-018-3868-4","article-title":"Studying the chemical reactivity properties of the target tumor-environment tripeptides NGR (asparagine-glycine-arginine) and RGD (arginine-glycine-aspartic acid) in their interactions with tamoxifen through conceptual density functional theory","volume":"24","year":"2018","journal-title":"J. Mol. Model."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2008.09.005","article-title":"Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin","volume":"133","author":"Hong","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1039\/C4NR05200E","article-title":"Epidermal growth factor receptor-targeted lipid nanoparticles retain self-assembled nanostructures and provide high specificity","volume":"7","author":"Zhai","year":"2015","journal-title":"Nanoscale"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/ac062151b","article-title":"Aptamer-Conjugated Nanoparticles for the Collection and Detection of Multiple Cancer Cells","volume":"79","author":"Smith","year":"2007","journal-title":"Anal. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2016.11.014","article-title":"Tumor-targeted nanomedicines for cancer theranostics","volume":"115","author":"Arranja","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"109340","DOI":"10.1016\/j.biopha.2019.109340","article-title":"pH- and enzyme-triggered drug release as an important process in the design of anti-tumor drug delivery systems","volume":"118","author":"Cao","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","article-title":"pH-Sensitive nano-systems for drug delivery in cancer therapy","volume":"32","author":"Liu","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1016\/j.biomaterials.2012.09.016","article-title":"The use of pH-sensitive positively charged polymeric micelles for protein delivery","volume":"33","author":"Gao","year":"2012","journal-title":"Biomaterials"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1039\/C4TB01533A","article-title":"A redox-responsive drug delivery system based on RGD containing peptide-capped mesoporous silica nanoparticles","volume":"3","author":"Li","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.7150\/thno.23804","article-title":"Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route","volume":"8","author":"Xin","year":"2018","journal-title":"Theranostics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/jps.24291","article-title":"Tumor-Targeted Paclitaxel Delivery and Enhanced Penetration Using TAT-Decorated Liposomes Comprising Redox-Responsive Poly(Ethylene Glycol)","volume":"104","author":"Fu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jsps.2020.01.004","article-title":"Polymeric nanocarriers as stimuli-responsive systems for targeted tumor (cancer) therapy: Recent advances in drug delivery","volume":"28","author":"Alsehli","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/adhm.201600479","article-title":"Synergistic Combination of Multistage Magnetic Guidance and Optimized Ligand Density in Targeting a Nanoplatform for Enhanced Cancer Therapy","volume":"5","author":"Chiang","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1901058","DOI":"10.1002\/adhm.201901058","article-title":"Magnetic Nanoparticles in Cancer Therapy and Diagnosis","volume":"9","author":"Farzin","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"9335","DOI":"10.1021\/nn302148p","article-title":"Lipid\u2013Peptide Vesicle Nanoscale Hybrids for Triggered Drug Release by Mild Hyperthermia in Vitro and in Vivo","volume":"6","author":"Bossche","year":"2012","journal-title":"ACS Nano"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1039\/C5CS00798D","article-title":"Smart micro\/nanoparticles in stimulus-responsive drug\/gene delivery systems","volume":"45","author":"Karimi","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.biomaterials.2015.10.027","article-title":"Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release","volume":"75","author":"Luo","year":"2016","journal-title":"Biomaterials"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","article-title":"Ultrasound-mediated blood\u2013brain barrier disruption for targeted drug delivery in the central nervous system","volume":"72","author":"Aryal","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1021\/acsami.8b21488","article-title":"Protein-Induced Gold Nanoparticle Assembly for Improving the Photothermal Effect in Cancer Therapy","volume":"11","author":"Wang","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.biomaterials.2013.12.046","article-title":"Protein modified upconversion nanoparticles for imaging-guided combined photothermal and photodynamic therapy","volume":"35","author":"Chen","year":"2014","journal-title":"Biomaterials"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.actbio.2018.04.029","article-title":"Towards tailored management of malignant brain tumors with nanotheranostics","volume":"73","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7150\/ntno.21638","article-title":"Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer","volume":"2","author":"Sonali","year":"2018","journal-title":"Nanotheranostics"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/smll.201500997","article-title":"Preoperative Detection and Intraoperative Visualization of Brain Tumors for More Precise Surgery: A New Dual-Modality MRI and NIR Nanoprobe","volume":"11","author":"Li","year":"2015","journal-title":"Small"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Lungu, I.I., Grumezescu, A.M., Volceanov, A., and Andronescu, E. (2019). Nanobiomaterials Used in Cancer Therapy: An Up-To-Date Overview. Molecules, 24.","DOI":"10.3390\/molecules24193547"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"102008","DOI":"10.1016\/j.nano.2019.04.011","article-title":"pH and redox dual responsive carrier-free anticancer drug nanoparticles for targeted delivery and synergistic therapy","volume":"20","author":"Zhou","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/acs.biomac.9b00428","article-title":"Cancer-Selective Bioreductive Chemotherapy Mediated by Dual Hypoxia-Responsive Nanomedicine upon Photodynamic Therapy-Induced Hypoxia Aggravation","volume":"20","author":"Zhu","year":"2019","journal-title":"Biomacromolecules"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0090-4295(01)01192-X","article-title":"Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer","volume":"58","author":"Fowler","year":"2001","journal-title":"Urology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025013","article-title":"In situ forming depot as sustained-release drug delivery systems","volume":"36","author":"Kanwar","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Salvioni, L., Rizzuto, M.A., Bertolini, J.A., Pandolfi, L., Colombo, M., and Prosperi, D. (2019). Thirty years of cancer nanomedicine: Success, frustration, and hope. Cancers, 11.","DOI":"10.3390\/cancers11121855"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-019-00631-4","article-title":"PEGylation: A promising strategy to overcome challenges to cancer-targeted nanomedicines: A review of challenges to clinical transition and promising resolution","volume":"9","author":"Hussain","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: A strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of Clinical Translation of Cancer Nanomedicines\u2014Lessons Learned from Successes and Failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_177","unstructured":"(2020, August 27). Drug-Eluting Beads|Radiology Key. Available online: https:\/\/radiologykey.com\/drug-eluting-beads\/."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/11\/1028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:29:58Z","timestamp":1760178598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/11\/1028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":177,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["pharmaceutics12111028"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12111028","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]}}}